Stockscreener 앱 받기
14.21
7.06%
-1.08
시간 외 거래:
15.00
0.79
+5.56%
전일 마감가:
$15.29
열려 있는:
$15.05
하루 거래량:
105.27K
Relative Volume:
0.90
시가총액:
$124.09M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-710.50
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
+1.57%
1개월 성능:
+22.50%
6개월 성능:
-9.14%
1년 성능:
-22.32%
1일 변동 폭
$14.09
$15.55
1주일 범위
$13.51
$15.96
52주 변동 폭
$6.53
$26.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
14.21 | 120.38M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics Inc. Bounces Off Moving Average SupportReal Trader Watchlist of Hot Stocks Released - metal.it
Seres (MCRB) Q2 Loss Narrows 34% - AOL.com
Seres Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics - TipRanks
Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks - MSN
Seres Therapeutics Reports Q2 2025 Financial Results - TipRanks
Seres Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Seres Therapeutics: Unpacking Strategic Contradictions in Partnerships and FDA Engagements - AInvest
Seres Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MCRB) - Seeking Alpha
Sana Biotechnology shares fall 14.12% after-hours following Seres Therapeutics' board changes and clinical advancement updates. - AInvest
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss By Investing.com - Investing.com South Africa
Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss - Investing.com
Seres Therapeutics quarterly loss per share $2.27 - MarketScreener
Seres Therapeutics August 2025 slides: SER-155 shows 77% infection reduction - Investing.com
Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share - Yahoo Finance
Seres Therapeutics: A High-Conviction Biotech Buy Amid Clinical and Strategic Momentum - AInvest
Seres Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
Seres Therapeutics Inc. Stock Analysis and ForecastAchieve consistent profits with proven methods - Jammu Links News
Is Seres Therapeutics Inc. a growth stock or a value stockRapid portfolio appreciation - Jammu Links News
Is Seres Therapeutics Inc. a good long term investmentAchieve breakthrough gains with smart trades - Jammu Links News
How does Seres Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News
What are Seres Therapeutics Inc. company’s key revenue driversConsistent high-yield stocks - Jammu Links News
When is Seres Therapeutics Inc. stock expected to show significant growthInvest confidently with real-time data - Jammu Links News
What are analysts’ price targets for Seres Therapeutics Inc. in the next 12 monthsBuild a diversified portfolio for maximum returns - Jammu Links News
Should I hold or sell Seres Therapeutics Inc. stock in 2025Build a portfolio that grows with the market - Jammu Links News
What analysts say about Seres Therapeutics Inc. stockUnmatched profit potential - Jammu Links News
What makes Seres Therapeutics Inc. stock price move sharplyBuild wealth with steady, reliable stocks - Jammu Links News
Why is Seres Therapeutics Inc. stock attracting strong analyst attentionRetirement Planning Entry Points For Consistent Profits - Jammu Links News
Is Seres Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - metal.it
Seres Therapeutics: Speculative Gem with FDA Breakthrough Potential - AInvest
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough - Seeking Alpha
Why Seres Therapeutics Inc. stock attracts strong analyst attentionEntry Zone Strategy for Consistent Profit Shared - metal.it
What institutional investors are buying Seres Therapeutics Inc. stockPhenomenal wealth increase - Jammu Links News
How many analysts rate Seres Therapeutics Inc. as a “Buy”Build wealth with reliable stock picks - Jammu Links News
Will Seres Therapeutics Inc. Recover After Recent DeclineStock Market Entry Timing Signals Revealed - metal.it
What is the dividend policy of Seres Therapeutics Inc. stockSkyrocketing returns - Jammu Links News
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):